ArticleOncotarget2017
Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 4 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Global Epidemiology of PD-L1 Expression in Epstein-Barr Virus-Associated Gastric Cancer: A Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2025Pooled it
- Association of PD-L1 Expression with Clinicopathologic Characters in Gastric Cancer: A Comprehensive Meta-analysis.Current medicinal chemistry · 2024Pooled it
- Prognostic Implication of EBV Infection in Gastric Carcinomas: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Clinicopathological Significance of EBV-Infected Gastric Carcinomas: A Meta-Analysis.Medicina (Kaunas, Lithuania) · 2020Pooled it
- PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis.Discover oncology · 2022Review
- Clinicopathological and prognostic significance of programmed death ligant-1 expression in gastric cancer: a meta-analysis.Journal of gastrointestinal oncology · 2021Article
- Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.Diagnostic pathology · 2020Article
- Human papillomavirus as a driver of head and neck cancers.British journal of cancer · 2020Review
- Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial.Cancer research and treatment · 2019Article
- The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis.Cancer biology & medicine · 2018Article
- Article
- Programmed Death Ligand-1 Expression in Gastric Cancer Cases in Zambia.Journal of agricultural and biomedical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programmed death-ligand 1 (PD-L1) plays an essential protein for immune evasion, contributing to tumor development and progression. Recent studies have reported MET as an upregulator for PD-L1 overexpression through an oncogenic pathway. However, an association between PD-L1 expression with MET has not been reported in gastric cancer.The prognostic significance of PD-L1 and its association with Epstein-Barr virus (EBV), microsatellite instability (MSI), and mucin phenotype remain controversial. We performed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.